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Kif7, a member of the kinesin 4 superfamily, is implicated
in a variety of diseases including Joubert, hydrolethalus and
acrocallosal syndromes. It is also involved in primary cilium
formation and the Hedgehog signalling pathway and may
play a role in cancer. Its activity is crucial for embryonic
development. Kif7 and Kif27, a closely related kinesin in the
same subfamily, are orthologues of the Drosophila melano-
gaster kinesin-like protein Costal-2 (Cos2). In vertebrates,
they work together to fulﬁl the role of the single Cos2 gene in
Drosophila. Here, the high-resolution structure of the human
Kif7 motor domain is reported and is compared with that of
conventional kinesin, the founding member of the kinesin
superfamily. These data are a ﬁrst step towards structural
characterization of a kinesin-4 family member and of this
interesting molecular motor of medical signiﬁcance.
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1. Introduction
Members of the kinesin superfamily of motor proteins (Kifs)
move unidirectionally along microtubules (MTs) in an ATP-
dependent manner. They perform various functions and are
best known for their role in neuronal transport (Hirokawa et
al., 2009) and mitosis/cytokinesis. Kinesins have been impli-
cated in a range of diseases, usually related to their role in
cellular transport, transport of pathogens and cell division
(Mandelkow & Mandelkow, 2001).
Human Kif7 and Kif27, which are members of the kinesin-4
family (Katoh & Katoh, 2004a,b), are paralogues. They share
44% sequence identity overall and have even higher identity
in the motor domain (61%). They possess an N-terminal
globular motor domain that contains nucleotide-binding and
MT-interacting regions, followed by a stalk domain predicted
to form a discontinuous coiled coil and a globular C-terminal
tail domain (Fig. 1).
Figure 1
Bar diagrams of the human kinesin-4 family members (a) Kif7 and (b) Kif27. The globular motor domain
(MD, blue) is followed by the short neck linker (Neck, violet), a stalk predicted to form a discontinuous
coiled-coil region (red) and a C-terminal tail domain (grey).Both proteins are orthologues of the Drosophila melano-
gaster kinesin-like protein called Costal-2 (Cos2) that plays a
key role in Hedgehog (Hh) signalling. The Hedgehog ligands
[Sonic hedgehog (SHh), Indian hedgehog (IHh) and Desert
hedgehog (DHh)] are glycoproteins that play a crucial role
during embryogenesis (Bijlsma et al., 2004) and tumourigen-
esis (Magliano & Hebrok, 2003). Their signals are transduced
through the transmembrane proteins Patched 1 (Ptch 1),
Patched 2 (Ptch 2) and Smoothened (Smo). In the absence
of Hh proteins, Ptch-family members suppress Smo activity,
which becomes activated upon Hh ligand binding to the Ptch
proteins. These events lead to the activation of the transcrip-
tion factors Gli 1, Gli 2 and Gli 3. Direct interaction of the
MT-bound protein Cos2 with Cubitus interruptus (Ci) in the
cytoplasm is believed to be essential for its sequential phos-
phorylation by three distinct kinases, PKA, GSK  and CK1,
and subsequent proteosome-dependent cleavage. The gener-
ated fragment, CiR, diffuses into the nucleus, where it co-
represses Hh target genes (Tay et al., 2004; Wang et al., 2000).
Human Kif7 and Kif27, which are putative ciliary motors with
roles in the primary cilia, a sensory organelle (Verhey et al.,
2011), have been shown to interact with Gli transcription
factors and are believed to fulﬁl distinct functions in regulating
Gli proteins. Kif7, a critical regulator of mammalian Hh
signalling, acts as both a positive and negative regulator in the
Hh signalling pathway but performs this role differently from
Cos2 in that it does not interact with Smo or Fu (Endoh-
Yamagami et al., 2009). The current hypothesis suggests that
Kif7, as a plus-end-directed motor, transports Gli 2 away from
the cilium, thus preventing its activation (Goetz & Anderson,
2010). In contrast, Kif27 interacts with Fu, which takes part
in the construction of the primary cilium (Wilson et al., 2009).
Kif7 and Kif27 seem to work together in vertebrates to fulﬁl
the role of the single Cos2 gene in D. melanogaster.
There are several reports describing Kif7 mutant alleles in
mouse embryos and their characterization has shown the
critical role of Kif7 in primary cilia formation and Hh signal-
ling (Karel et al., 2009; Cheung et al., 2009; Endoh-Yamagami
et al., 2009). One of these alleles carried a Kif7L130P mutation
and caused death of mouse embryos at the end of gestation.
In humans, various Kif7 mutations have been linked to
a range of neurodegenerative diseases, including Joubert
(Daﬁnger et al., 2011), hydrolethalus and acrocallosal syn-
dromes (Putoux et al., 2011). In addition, since inappropriate
activation of Hh signalling can lead to the formation of
medulloblastomas, rhabdomyosarcomas, basal carcinomas and
other tumour types (Goetz & Anderson, 2010) and given
the role of Kif7 in human primary cilia formation and Hh
signalling (Karel et al., 2009), Kif7 might also be linked to
other diseases such as cancer.
In our effort to characterize human kinesins of medical
interest, we report here the crystal structure of the human Kif7
motor domain to 1.6 A ˚ resolution. We compare this crystal
structure with that of the founding member of the kinesin
superfamily, conventional kinesin (kinesin-1 family). This
is the ﬁrst step towards the structural characterization of a
kinesin-4 family member.
2. Materials and methods
2.1. Cloning, protein expression and purification
Codon-optimized cDNAs for Kif78–361 and Kif271–341 were
purchased from GenScript and cloned into a modiﬁed pET-
M20 Escherichia coli expression vector carrying an N-terminal
Trx-fusion protein, a His tag and a TEV (tobacco etch virus)
cleavage site. The sequences were veriﬁed by DNA sequen-
cing. Subsequently, we cloned shorter constructs using the
following forward and reverse primers: Kif78–347,5 0-CGT GCC
CAG TAA* ATC CGC AAC CGC GCC AC-30;K i f 2 7 1–339,5 0-
GCG AAC CGC GCG CGT TAG* ATT CTC GAG TAA
TCG-30; Kif276–341,5 0-CT ATG GAA GCC ATG GCG GTG
AAA GTT GCG-30,5 0-GT GGT GCT CGA TTA CTC GAG
AAT GTTACG C-30; Kif2717–341,5 0-GTATT CGT CCC ATG
GTG TGC AAAGAA GCG-30,5 0-GT GGT GCT CGATTA
CTC GAG AAT GTT ACG C-30. The Kif7 single point
mutation (Kif78–347L130P) was cloned employing the Quik-
Change Kit (Roche) with the following mutagenesis primer:
50-C GAA GCC TTC AAA CCG ATC GAT GAA AAC
GAC C-30. All proteins were expressed in E. coli BL21 (DE3)
pLysS expression cells (Novagen). Bacteria were grown in
Terriﬁc Broth (TB) medium (Sigma) at 310 K to an A600 of 0.7
and were subsequently induced with 0.5 mM isopropyl  -d-1-
thiogalactopyranoside (IPTG; Sigma) at a temperature of
291 K. Overnight cultures were centrifuged (20 min, 277 K,
3300g) and resuspended in lysis buffer. Cells were lysed by
sonication (eight cycles of 8 s on/off as 20 ml lysate fractions)
and centrifuged (1 h, 277 K, 31 400g). Supernatants were
pooled and the proteins were puriﬁed by afﬁnity chromato-
graphy [1 ml HisTrap FF (GE Healthcare); buffer A,5 0m M
piperazine-N,N0-bis(2-ethanesulfonic acid) (PIPES) pH 7.0,
250 mM NaCl, 2 mM MgCl2,4 0m M imidazole (Sigma); buffer
B,5 0m M PIPES pH 7.0, 250 mM NaCl, 2 mM MgCl2, 500 mM
imidazole], followed by overnight cleavage with TEV protease
(0.05 mg TEV per milligram of protein). Prior to TEV clea-
vage, the buffer was exchanged to eliminate imidazole from
the protein solution (HiPrep 26/10, GE Healthcare; 50 mM
PIPES pH 7.0, 250 mM NaCl, 2 mM MgCl2). Subsequently,
His-tagged Trx and TEV were removed by a second run on a
His-trap afﬁnity column. The ﬁnal step of puriﬁcation
consisted of gel ﬁltration (Superose S75; GE Healthcare) in
gel-ﬁltration buffer [50 mM PIPES pH 7.0, 250 mM NaCl,
2m M MgCl2,1m M dithiothreitol (DTT; Sigma)].
2.2. Crystallization
All Kif7 and Kif27 constructs described above were used
for crystallization trials at 10 mg ml
 1 at 277 and 292 K in the
presence and absence of 1 mM Mg
2+ATP. The crystallization
screens used were ComPAS, JCSG+, PACT (all from Qiagen),
Ammonium Sulfate Grid Screen, Sodium Malonate Grid
Screen, MPD Grid Screen, Crystal Screen HT, Crystal Screen
Lite, PEG/Ion, PEG 6000 and PEG LiCl (all from Hampton
Research). Kif78–347 crystals grew in 20%(w/v) PEG 3350
in the presence of various salts (0.1 M magnesium formate
dihydrate, 0.2 M lithium acetate, 0.2 M potassium sodium
tartrate tetrahydrate, 0.1 M sodium acetate, 0.2 M ammonium
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Acta Cryst. (2012). D68, 154–159 Klejnot & Kozielski   Kif7 155nitrate, 0.2 M sodium nitrate). However, the best crystals were
obtained in the presence of lithium acetate. All other protein
constructs did not yield crystals under the conditions tested.
2.3. Analytical gel filtration
Analytical gel ﬁltration was performed to determine the
oligomeric state of the proteins (Superose 12 10/300 GL, GE
Healthcare; buffer 50 mM PIPES pH 7.0, 250 mM NaCl, 2 mM
MgCl2,1m M DTT). Experiments were conducted using a ﬂow
rate of 1 ml min
 1 and an injection volume of 250 ml. Prior
to running Kif78–347 and Kif271–341 constructs, the column was
calibrated with proteins of known molecular mass (ribo-
nuclease A, 16.7 kDa; carbonic anhydrase, 14.5 kDa; oval-
bumin, 13.5 kDa; conalbumin, 13.0 kDa) and dextran blue.
The Kav values were calculated for calibration proteins
[(Ve   V0)/(Vc   V0), where Ve is the elution volume, V0 is the
void volume and Vc is the column volume)] and plotted
against the log of the molecular weights of the standards. The
molecular masses of Kif78–347 and Kif271–341 were calculated
from the resulting equation. The identities of the proteins
were conﬁrmed by mass spectrometry ﬁngerprint analyses.
2.4. Data collection, structure determination and model
refinement
Kif78–347 crystals grown in 0.2 M lithium acetate, 20%(w/v)
PEG 3350 on a microscale in hanging drops consisting of a 1:1
ratio of protein and reservoir solutions were transferred to
cryoprotectant solution [20%(w/v) meso-erythritol (Sigma),
0.24 M lithium acetate and 24%(w/v) PEG 3350, 0.06 M Pipes,
0.3 M NaCl, 2.4 mM MgCl2, 1.2 mM DTT, 2.4 mM Mg
2+ATP]
and ﬂash-cooled in liquid nitrogen. Data were collected on
beamline I04-1 at Diamond Light Source and were processed
with XDS (Kabsch, 2010) to 1.6 A ˚ resolution in space group
P212121. The structure was solved by molecular replacement
with MOLREP (Vagin & Teplyakov, 2010) using the Kif3B
structure (PDB entry 3b6v; Structural Genomics Consortium,
unpublished work) as a search model. The asymmetric unit
contained one copy of Kif78–347 with bound Mg
2+ADP posi-
tioned with REFMAC5 (Murshudov et al., 2011) by rigid-body
and restrained reﬁnement. The model was subsequently
improved with Coot (Emsley et al., 2010) and further reﬁned
using PHENIX with TLS restraints (Zwart et al., 2008).
2.5. Determination of protein concentrations
Protein concentrations were determined using the
Beer–Lambert law with molar extinction coefﬁcients (")
of 10 430 mol cm
 1 for Kif78–347 and 18 910 mol cm
 1
for Kif278–347, taking bound ADP into account
("ADP = 2500 mol cm
 1), or by the Bradford method. Both
methods yielded very similar protein concentrations, with
differences of <10%.
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Figure 2
SDS–PAGE of gel-ﬁltration proﬁles of (a) Kif78–347 and (b) Kif271–341.
The left lane contains molecular-weight markers (labelled in kDa).
Table 1
Data-collection and reﬁnement statistics for human Kif78–347.
Values in parentheses are for the highest resolution shell.
PDB entry 4a14
Beamline/detector I04-1/Pilatus 2M
Resolution range (A ˚ ) 30–1.6
Space group P212121
Unit-cell parameters (A ˚ ,  ) a = 45.99, b = 79.80, c = 95.05,
  =   =   = 90.0
Completeness (%) 99.9 (100)
Rmerge (%) 3.2 (43.1)
Multiplicity 7.5 (7.5)
Mean I/ (I) 30.1 (4.4)
No. of unique reﬂections 46998 (6746)
No. of copies per asymmetric unit 1
Reﬁnement statistics
Rwork/Rfree (%) 18.25/20.67
No. of Mg
2+ADP/waters 1/328
R.m.s.d. from ideal geometry
Bond lengths (A ˚ ) 0.011
Bond angles ( ) 1.547
Average B factors (A ˚ 2)
Protein 27.6
Solvent 39.9
Ramachandran plot
Residues in favoured regions (%) 98.7
Residues in allowed regions (%) 1.3
Outliers (%) 0.02.6. Western blot
1 l cultures of native Kif78–347 and of Kif78–347L130P were
grown, harvested and lysed as described previously. Subse-
quently, supernatants and pellets were analyzed separately.
Supernatants were diluted tenfold. 200 ml of pellets was
resuspended and boiled in 2 ml 6 M urea and diluted tenfold.
SDS–PAGE was run with the following ratio: 10 ml sample,
8 ml loading buffer and 2 ml reducing agent. Proteins were then
transferred onto nitrocellulose membrane (30 V, 400 mA, 1 h
20 min) in NuPAGE transfer buffer (Invitrogen) supplied with
20% methanol. The membrane was subsequently blocked
overnight at 277 K using a solution of 5% milk powder in
TBS-T (Tris-buffered saline/Tween-20). The blocking solution
was washed out with three cycles of 5 min washes with TBS-T
and the membrane was incubated in 1% milk solution con-
taining the 6 His mAb-HRP conjugate (Clontech) for 1 h at
room temperature. After incubation, the excess conjugate was
removed by three washes with TBS-T (5 min each) and a ﬁnal
rinse (5 min) in water. Finally, the membrane was developed
with BM Chemiluminescence Western Blotting Substrate
(Roche).
3. Results and discussion
Human Kif7 and Kif27 possess an N-terminal motor domain
that contains nucleotide-binding and MT-interacting regions
followed by a discontinuous  -helical
region predicted to form a coiled coil
responsible for oligomerization and a
C-terminal globular tail domain (Fig. 1).
Mass spectrometry ﬁngerprint analysis
with coverage of 56 and 49% conﬁrmed
that the recombinantly expressed and
puriﬁed proteins were in fact Kif7 and
Kif27. Analytical gel ﬁltration showed
that both constructs were monomeric
(38 and 36 kDa), as expected for kinesin
motor domains. Both proteins were
>95% pure as judged by SDS–PAGE
(Fig. 2). Of the seven Kif7 and Kif27
constructs used for crystallization, only
Kif78–347, which lacks the neck linker
region, yielded crystals. Kif78–347 crys-
tallized as a monomer with one mole-
cule per asymmetric unit. Data were
collected to 1.6 A ˚ resolution and the
structure thus belongs to a small group
of kinesins solved to a higher resolution.
Data-collection and reﬁnement statis-
tics are summarized in Table 1. The ﬁnal
structure included residues 12–347
(missing regions: 107–114, 207–211,
230–241, 260–273) with bound
Mg
2+ADP (octahedrally coordinated)
in the catalytic site and 328 water
molecules. The reﬁned structure
contained 98.7% of residues in the most
favourable region, 1.3% in allowed
regions and no outliers. Fig. 3(a)
presents the front and the back views of
the overall structure of the Kif7 motor
domain. Kif7 contains an eight-stranded
 -sheet core with three major solvent-
exposed  -helices on each side,
displaying the characteristic arrowhead-
like structure typical of all members of
the kinesin superfamily solved to date
(Kull et al., 1996).
Subsequently, we compared the Kif7
structure with that of conventional
research papers
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Figure 3
(a) Overall structure of Kif78–347 in complex with Mg
2+ADP (ball-and-stick model).  -Helices are
shown in blue,  -strands are coloured red and loop regions are shaded in grey. The switch II cluster
(helix  4/loop L12/helix  5) and the end of helix  6 preceding the neck linker region (not visible in
this structure), which are thought to be pivotal for force generation in kinesins, are coloured orange.
(b) Stereo-plot of helix  2 residues 128–132. The 2Fo   Fc map (coloured in blue) is contoured at
1 . A single mutation in this region (L130P) causes embryonic lethality in mice.kinesin, the founding member of the kinesin superfamily.
Alignment of Kif78–347 with conventional kinesin (Kif5b)
revealed their high structural similarity (Fig. 4). The sequence
identity between the motor domains of Kif5b and Kif7 is 37%.
There are two single insertions in the loop L2 region in the
small three-stranded antiparallel  -sheet of Kif7. The P-loop
or Walker motif (phosphate-binding region) is conserved in
both proteins. In both structures, helix  2 is interrupted by
loop L5, a highly important region for inhibitor binding in the
mitotic kinesin Eg5. Kif7 contains a three-residue insertion
in this loop. Although we could see some electron density for
loop L5, residues Ala107–Glu114 are missing owing to its
increased length and higher ﬂexibility. In Kif7, the end of the
second part of helix  2 has a single-residue deletion compared
with Kif5b.Another two-residue insertion in Kif7 occurs in the
loop L8 region, which is fully visible in the structure. Only
residues Val159–Thr161 have an unclear density, which may
suggest a dual conformation of this part of the loop. In Kif5b
the switch I region (residues 199–205) consists of a small helix
( 3a), whereas in Kif7 it forms a loop (L9). In Kif7 there is an
eight-residue long insertion in loop L10; this region is disor-
dered and is not visible in our structure. Switch II (Asp251–
Glu257), which is highly conserved in both proteins and
typically disordered in kinesins, is not fully visible in our
Kif79–349 structure. The switch II cluster (helix  4/loop L12/
helix  5) is in the so-called ‘down’ or ‘obstructive’ position
and one would expect the neck linker (Arg350–Asn356) to be
either unstructured or structured but in an undocked position
with respect to the motor domain. However, the neck linker is
not included in our protein owing to the short length of the
Kif7 construct used for crystallization. Kif78–361 contained the
neck-linker region but did not crystallize, whereas Kif78–347
lacking the neck linker revealed that the C-terminal residue
Gln347 shows crystal contacts indicating that there would not
be space for a neck linker in this crystal form. This might
explain why the longer Kif7 construct did not yield crystals.
The loop L11 region (Leu260–Ile273) is missing as in most
other kinesin structures. Kif7 contains a three-residue inser-
tion in loop L12 which is fully visible.
We also solved a mutated Kif7 motor-domain structure
(PDB entry 2xt3). Despite four point mutations (Kif7E226K,
Kif7R268L, Kif7L269R and Kif7H295N), the overall structure of
the motor domain remained unchanged (data not shown).
In summary, the structure of human Kif7 resembles that of
human conventional kinesin.
As previously mentioned, mutations in Kif7 alleles can
disturb Hh signalling, leading to death of mouse embryos. For
example, in mouse models a single mutation in the Kif7 motor
domain (L130P) caused early embryonic lethality at
the gestation stage. This mutation was introduced through
N-ethyl-N-nitrosourea induction
in order to determine the impact
on Hh signalling (Karel et al.,
2009). To understand how a single
mutation in Kif7 can lead to such
a dramatic event, we wanted to
investigate the structure of the
mutant. The construct carrying
the mutation was expressed in E.
coli but was insoluble (Fig. 5).
Nevertheless, the structure of
native Kif7 reveals that the L130P
mutation would be situated at the
end of the second half of the
interrupted helix  2( F i g .3 b). We
speculate that the mutation of
leucine to proline, a known ‘helix
breaker’, could cause a signiﬁcant
change to the secondary structure
of the protein in this region.
Another possibility could be that
mutated Kif7 is degraded or
aggregates in vivo owing to its
misfolding. Also, there is one C—
H—  interaction between
Leu130 and Phe83 that is lost
when leucine is mutated to
proline.
In conclusion, we have pro-
vided structural insights into the
human Kif7 motor domain, a
kinesin that is potentially impli-
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Figure 4
Sequence alignment and secondary-structure elements derived from the crystal structures of the Kif5b
(conventional kinesin, kinesin-1; PDB entry 1bg2; Kull et al., 1996) and Kif7 motor domains. The
numbering relates to residues of Kif5b. Identical residues are coloured in white on a red background;
similar residues are shaded in red. The ATP-binding pocket and the switch regions (N1–N4) are underlined
in black.cated in several diseases. In the future, it will be interesting
to determine whether Kif7 and its closely related paralogue
Kif27 are proteins that are worth targeting in the Hedgehog
signalling pathway (Sarangi et al., 2009).
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Figure 5
Western blot of soluble and insoluble fractions of Kif78–347 and Kif78–
347L130P. Lanes M contain molecular-weight markers (labelled in kDa).